You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,916,606


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,916,606
Title:Therapeutic compositions and methods for targeted delivery of active agents
Abstract: The present invention pertains to therapeutic compositions that comprise: (1) a nanovector, (2) an active agent; and (3) a targeting agent, wherein the active agent and the targeting agent are non-covalently associated with the nanovector. The present invention also pertains to methods of treating various conditions in a subject by utilizing the above-described therapeutic compositions. Methods of making the therapeutic compositions are also a subject matter the present invention.
Inventor(s): Tour; James M. (Bellaire, TX), Berlin; Jacob (Monrovia, CA), Pham; Tam (Renton, WA), Myers; Jeffrey N. (Bellaire, TX), Sano; Daisuke (Yokohama, JP)
Assignee: William Marsh Rice University (Houston, TX) Board of Regents, The University of Texas System (Austin, TX)
Application Number:13/504,716
Patent Claims:1. A therapeutic composition comprising: a. a nanovector, wherein said nanovector comprises an oxidized and ultra-short single-walled carbon nanotube (US-SWNT), wherein said US-SWNT has open ends, wherein said US-SWNT has lengths ranging from 20 nm to 80 nm, wherein said nanovector is polyethylene-glycol-functionalized, and wherein said nanovector is soluble in water; b. an active agent non-covalently associated with said nanovector, wherein said active agent comprises an anti-cancer drug; and c. a targeting agent non-covalently associated with said nanovector, wherein said targeting agent comprises an antibody.

2. The therapeutic composition of claim 1, wherein said active agent is selected from the group consisting of small molecules, proteins, DNA, antisense oligonucleotides, miRNA, siRNA, and aptamers.

3. The therapeutic composition of claim 1, wherein said active agent is Paclitaxel.

4. The therapeutic composition of claim 1, wherein said targeting agent comprises a monoclonal antibody.

5. The therapeutic composition of claim 1, wherein said targeting agent is an anti-epidermal growth factor receptor antibody.

6. A method of treating a condition in a subject, said method comprising administering a therapeutic composition to said subject, wherein said therapeutic composition comprises: a. a nanovector, wherein said nanovector comprises an oxidized and ultra-short single-walled carbon nanotube (US-SWNT), wherein said US-SWNT has open ends, wherein said US-SWNT has lengths ranging from 20 nm to 80 nm, wherein said nanovector is polyethylene-glycol-functionalized, and wherein said nanovector is soluble in water; b. an active agent non-covalently associated with said nanovector, wherein said active agent comprises an anti-cancer drug; and c. a targeting agent non-covalently associated with said nanovector, wherein said targeting agent comprises an antibody.

7. The method of claim 6, wherein said active agent comprises Paclitaxel, and said targeting agent comprises Cetuximab.

8. The method of claim 6, wherein said subject is a human being.

9. The method of claim 6, wherein said administering said therapeutic agent comprises intravenous administration.

10. The method of claim 6, further comprising administering radiation to said subject before, during or after said administering of said therapeutic composition.

11. A method of making a therapeutic composition, said method comprising: a. non-covalently associating a nanovector with an active agent wherein said active agent comprises an anti-cancer drug, and wherein said nanovector comprises an oxidized and ultra-short single-walled carbon nanotube (US-SWNT), wherein said US-SWNT has open ends, wherein said US-SWNT has lengths ranging from 20 nm to 80 nm, wherein said nanovector is polyethylene-glycol-functionalized, and wherein said nanovector is soluble in water; and b. non-covalently associating a targeting agent with said nanovector, wherein said targeting agent comprises an antibody.

12. The method of claim 11, wherein said associating of said nanovector with said active agent occurs by sequestration.

13. The method of claim 11, wherein said associating of said nanovector with said targeting agent occurs by sequestration.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.